10-Q: Phio Pharmaceuticals Reports Q2 2024 Results, Cites Cost Rationalization and Clinical Trial Progress

Phio Pharmaceuticals reported its Q2 2024 financial results, highlighting cost rationalization efforts and progress in its PH-762 clinical trial.

Summary

• Phio Pharmaceuticals reported a net loss of $1.846 million for the three months ended June 30, 2024, and a net loss of $4.0 million for the six months ended June 30, 2024.
• The company's operating expenses decreased to $1.914 million for the three months ended June 30, 2024, and $4.123 million for the six months ended June 30, 2024, due to cost rationalization efforts.
• Research and development expenses decreased to $866,000 for the three months ended June 30, 2024, and $2.014 million for the six months ended June 30, 2024.
• General and administrative expenses decreased to $1.048 million for the three months ended June 30, 2024, and $2.109 million for the six months ended June 30, 2024.
• The company's cash and cash equivalents were $4.698 million as of June 30, 2024.
• Phio completed a 1-for-9 reverse stock split on July 5, 2024.
• The company terminated its clinical co-development agreement with AgonOx in May 2024.
• The Phase 1b clinical trial for PH-762 is ongoing and expects to complete enrollment in the second quarter of 2025.
• The company estimates that its current cash and cash equivalents will fund operations into Q2 2025.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in its clinical trial and reduced costs, the significant losses, limited cash runway, and going concern warning create a negative sentiment. The recent financing provides some relief, but the overall outlook is still uncertain.

Positives

• The company has successfully reduced operating expenses through cost rationalization measures.
• The Phase 1b clinical trial for PH-762 is progressing with positive safety data and dose escalation.
• The termination of the AgonOx agreement eliminates future financial obligations and uncertainties.
• The company completed a financing in July 2024, raising approximately $2.6 million in net proceeds.
• The company has a clear focus on product development with PH-762.

Negatives

• The company reported a net loss of $1.846 million for the three months ended June 30, 2024, and a net loss of $4.0 million for the six months ended June 30, 2024.
• The company has limited cash resources and has reported recurring losses since inception.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company terminated its clinical co-development agreement with AgonOx.
• The company has not yet received product revenues.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional funding.
• There is no guarantee that additional funding will be available on acceptable terms, or at all.
• Failure to obtain additional funding could force the company to scale back or terminate operations.
• The company is subject to the risks associated with clinical trials, including delays and negative results.
• The company may not be able to maintain compliance with the continued listing requirements of The Nasdaq Capital Market.
• The company's actual results and financial condition may differ materially from those indicated in forward-looking statements.

Future Outlook

The company expects that its current cash and cash equivalents will enable it to fund its current operating plan into Q2 2025. The company will continue to assess its cash and cash equivalents and future funding requirements.

Management Comments

• The company implemented a cost rationalization program in 2023, driven by its transition from a research company to a product development company.
• The company has redirected expense reductions to funding the Phase 1b clinical trial with PH-762 directed toward skin cancer.
• The company believes that direct-to-tumor administration of PH-762 resulted in activity against distant untreated tumors, indicative of a systemic anti-tumor response.
• The company believes its INTASYL compounds can improve immune cells to make them more effective in killing cancer.

Industry Context

Phio's focus on immuno-oncology and RNA gene silencing aligns with current trends in cancer therapeutics. The development of PH-762, targeting PD-1, is a common approach in the field. The termination of the AgonOx collaboration reflects the challenges and risks inherent in biotech partnerships.

Comparison to Industry Standards

• Phio's cash burn rate is typical for a clinical-stage biotech company, but the company's limited cash runway raises concerns about its ability to continue operations without additional funding.
• The company's focus on a Phase 1b trial is consistent with the development pathway for early-stage therapeutics, but the timeline for completion is relatively long.
• The termination of the AgonOx collaboration is not uncommon in the biotech industry, where partnerships can be difficult to maintain.
• The company's cost rationalization efforts are a common response to financial pressures in the biotech sector.
• The reverse stock split is a common strategy for companies facing delisting from major exchanges.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment if the company is unable to secure additional funding.
• Employees may be affected by potential further cost-cutting measures or if the company is unable to continue operations.
• Customers and suppliers may be impacted by the company's financial instability and potential operational changes.
• Creditors face the risk of non-payment if the company is unable to continue as a going concern.

Next Steps

• The company will continue to enroll patients in the Phase 1b clinical trial for PH-762, with expected completion in the second quarter of 2025.
• The company will continue to assess its cash and cash equivalents and future funding requirements.
• The company will seek additional funding to sustain its future operations.

Key Dates

Keywords

Phio Pharmaceuticals, INTASYL, PH-762, immuno-oncology, clinical trial, cost rationalization, biotechnology, RNA gene silencing, PD-1, financing